Method for quantifying active orexin A
By identifying the C-terminal monoclonal antibody and mass spectrometry analysis technology of orexin A, the identification bias of orexin A quantification in the prior art was solved, and the accurate quantification of active orexin A in cerebrospinal fluid was achieved to assist in the diagnosis of orexin. A. Diseases such as deficiency and sleep disorders.
Patent Information
- Application Number
- CN202380026755.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-04-11
- Filing Date
- 2023-04-10
- Publication Date
- 2024-11-19
AI Technical Summary
The existing radioimmunoassays have deviations in identifying orexin A metabolites when determining orexin A concentration in cerebrospinal fluid, and the truncated metabolites do not have the activity to maintain awakening, resulting in quantitative activity type of orexin A. Difficult to proceed accurately.
The C-terminal monoclonal antibody that recognizes orexin A was used for isolation, and the metabolites that were not metabolized without metabolic orexin A and its C-terminal partial truncation were quantified by protease digestion and mass spectrometry, combined with solid phase extraction and liquid chromatography technology. , ensure the accuracy of quantification.
The accurate amount of active orexin A in cerebrospinal fluid is achieved, which can assist in the diagnosis of orexin A deficiency, sleep disorders and neurodegenerative diseases, and improve the accuracy and reliability of the diagnosis.
Smart Images

Figure HDA0005036461760000011 
Figure HDA0005036461760000021 
Figure HDA0005036461760000031
Abstract
Description
Technical Field
[0001] The present disclosure relates to a method for quantifying active orexin A. Background Art
[0002] Orexin is a neurotransmitter in the brain that is involved in maintaining wakefulness. Orexin exists in two isopeptides, one of which is orexin A. For example, narcolepsy, which is known to cause excessive sleepiness (narcolepsy), is a disease caused by the loss of orexin neurons, and the concentration of orexin A in the brain (cerebrospinal fluid) of narcolepsy patients is significantly lower.
[0003] Hypersomnia is not limited to narcolepsy, but can also be seen in various neurodegenerative diseases. For example, Parkinson's patients often suffer from daytime sleepiness in addition to movement disorders. The concentration of orexin A in the cerebrospinal fluid of Parkinson's patients was measured using the radioimmunoassay (RIA) manufactured by Phoenix, which is currently widely used. The result showed that the concentration of orexin A tended to decrease, but the change was small and the deviation was large (Non-Patent Document 1).
[0004] Recent research results on orexin A in cerebrospinal fluid have shown that orexin A can be recognized by the anti-orexin A polyclonal antibody used in the currently widely used radioimmunoassay (RIA) manufactured by Phoenix Incorporated (or equivalent products), most of which are truncated and exist as metabolites in the cerebrospinal fluid (Non-Patent Document 2).
[0005] On the other hand, the literature indicates that truncated orexin A metabolites do not have activity related to maintaining wakefulness (Non-patent Literature 3), which suggests that the activity of orexin A inherent in maintaining wakefulness may be limited to the intact form that has not been metabolized, or to the orexin A type whose metabolism (truncation) is limited to the C-terminal part even if it is metabolized.
[0006] Prior art literature
[0007] Non-patent literature
[0008] [Non-patented document 1] Miriam, W., et al., "Progressive dopamine and hypocretin deficiency in Parkinson's disease: are there effects on sleep and wakefulness?" J Sleep Res. 2012 Dec;21(6):710-717.
[0009] [Non-patent document 2] Sakai, N., Matsumura, M., Lin, L et al., "HPLC analysis of hypocretin-1 in cerebrospinal fluid of patients with narcolepsy type 1 and type 2." Scientific Reports 9, 477 (2019).
[0010] [Non-patent document 3] Manja, L et al., "Structural activity studies of orexin A and orexin B on human orexin 1 and orexin 2 receptors yielded orexin 2 receptor selective ligands and orexin 1 receptor preferential ligands", J. Med. Chem. 2004, 47, 5, 1153-1160 Summary of the invention
[0011] Problem that the invention aims to solve
[0012] The present disclosure aims to provide a method for quantifying active orexin A.
[0013] Technical solutions to the problem
[0014] In view of the above circumstances, the present inventors have conducted intensive studies and, as a result, have found a method for specifically quantifying active orexin A present in cerebrospinal fluid, thereby completing the present specification.
[0015] That is, this specification relates to the following [1] to
[24] .
[0016] [1] A method for quantifying active orexin A in a sample, comprising:
[0017] a step of contacting the sample with a monoclonal antibody that recognizes the C-terminal side of orexin A to separate orexin A;
[0018] The step of digesting the separated orexin A class with a protease to obtain a peptide consisting of the amino acid sequence represented by SEQ ID NO: 1; and
[0019] Steps for mass spectrometry analysis of the above peptides.
[0020] [2] The method according to [1], further comprising the step of purifying the peptide by solid phase extraction before performing the mass spectrometry analysis.
[0021] [3] The method according to [1] or [2], further comprising the step of performing high performance liquid chromatography before performing the mass spectrometry analysis.
[0022] [4] The method according to any one of [1] to [3], wherein the orexin A class is isolated by immunoprecipitation.
[0023] [5] A method for quantifying active orexin A in a sample collected from a subject using the method described in any one of [1] to [4], and assisting in the diagnosis of orexin A deficiency, sleep disorders, neurodegenerative diseases or traumatic brain injury based on the quantitative results.
[0024] [6] The method according to [5], which is a method for assisting the diagnosis of neurodegenerative diseases.
[0025] [7] A method for quantifying active orexin A in a sample collected from a subject using the method described in any one of [1] to [4], and diagnosing orexin A deficiency, sleep disorder, neurodegenerative disease or traumatic brain injury based on the quantitative result.
[0026] [8] The method according to [7], which is a method for diagnosing a neurodegenerative disease.
[0027] [9] The method according to any one of [5] to [8], wherein the sample collected from the subject is cerebrospinal fluid.
[0028]
[10] The method according to any one of [5] to [9], wherein the neurodegenerative disease is synucleinopathy or tauopathy.
[0029]
[11] The method according to any one of [5] to
[10] , wherein the neurodegenerative disease is Parkinson's disease, Alzheimer's disease or mild cognitive impairment.
[0030]
[12] The method according to [3], wherein the orexin A class is separated by immunoprecipitation.
[0031]
[13] A method for quantifying active orexin A in a sample collected from a subject using the method described in
[12] , and assisting in the diagnosis of orexin A deficiency, sleep disorders, neurodegenerative diseases or traumatic brain injury based on the quantitative results.
[0032]
[14] The method according to
[13] is a method for assisting the diagnosis of neurodegenerative diseases.
[0033]
[15] The method according to
[13] , wherein the sample collected from the subject is cerebrospinal fluid.
[0034]
[16] The method according to
[13] , wherein the neurodegenerative disease is synucleinopathy or tauopathy.
[0035]
[17] The method according to
[13] , wherein the neurodegenerative disease is Parkinson's disease, Alzheimer's disease or mild cognitive impairment.
[0036]
[18] A method for quantifying active orexin A in a sample collected from a subject using the method described in
[12] , and diagnosing orexin A deficiency, sleep disorder, neurodegenerative disease, or traumatic brain injury based on the quantitative result.
[0037]
[19] The method according to
[18] , which is a method for diagnosing a neurodegenerative disease.
[0038]
[20] The method according to
[18] , wherein the sample collected from the subject is cerebrospinal fluid.
[0039]
[21] The method according to
[18] , wherein the neurodegenerative disease is synucleinopathy or tauopathy.
[0040]
[22] The method according to
[18] , wherein the neurodegenerative disease is Parkinson's disease, Alzheimer's disease or mild cognitive impairment.
[0041]
[23] A method for quantifying active orexin A in a sample collected from a subject using the method described in any one of [1] to [4], and determining a circadian rhythm based on the quantification result.
[0042]
[24] The method according to
[23] , wherein the sample collected from the subject is cerebrospinal fluid.
[0043] Effects of the Invention
[0044] According to the present disclosure, a method for quantifying active orexin A can be provided. BRIEF DESCRIPTION OF THE DRAWINGS
[0045] Figure 1 The diagram shows a peptide to be quantified in Example 1 (a peptide consisting of the amino acid sequence represented by SEQ ID NO: 1) and a graph showing the quantification result.
[0046] Figure 2 The diagram shows a peptide to be quantified in Comparative Example 1 (a peptide consisting of the amino acid sequence represented by SEQ ID NO: 2) and a graph showing the quantification result.
[0047] Figure 3 The diagram shows a peptide to be quantified in Comparative Example 2 (a peptide consisting of the amino acid sequence represented by SEQ ID NO: 1) and a graph showing the quantification result.
[0048] Figure 4 The graph shows the quantitative results of active orexin A in the cerebrospinal fluid of healthy subjects, patients with Parkinson's disease, patients with Alzheimer's disease, and patients with mild dementia.
[0049] Figure 5 The graph shows the correlation between the amount of active orexin A and the amount of orexin A metabolite (orexin A truncated at the C-terminus) in the cerebrospinal fluid of healthy individuals, Parkinson's disease patients, Alzheimer's disease patients, and mild dementia patients.
[0050] Figure 6 This is a graph showing the temporal changes in the amount of active orexin A in the cerebrospinal fluid of healthy subjects.
[0051] Figure 7 This is a graph showing the temporal changes in the amount of orexin A in the cerebrospinal fluid of healthy individuals. DETAILED DESCRIPTION
[0052] The method of the present invention is described in detail below. In the amino acid sequence represented by sequence number 1 (XPLPDCCR: sequence number 1), the X at the N-terminus represents a pyroglutamic acid residue. In the amino acid sequence represented by sequence number 2 (LYELLHGAGNHAAGILTX: sequence number 2), the X at the C-terminus represents an amidated leucine residue. In the amino acid sequence represented by sequence number 3 (XPLPDCCRQKTCSCRLYELLHGAGNHAAGILTX: sequence number 3), the X at the N-terminus represents a pyroglutamic acid residue, and the X at the C-terminus represents an amidated leucine residue. The amino acid sequence represented by sequence number 4 is TCSCR: sequence number 4.
[0053] One embodiment of the present disclosure involves a method for quantifying active orexin A, comprising: a step of separating orexin A class by contacting a sample with a monoclonal antibody that recognizes the C-terminal side of orexin A; a step of digesting the separated orexin A class with a protease to obtain a peptide consisting of an amino acid sequence represented by sequence number 1; and a step of performing mass spectrometry analysis on the peptide.
[0054] Orexin A is a general term for intact orexin A that has not been metabolized and its metabolites.
[0055] Active orexin A is a general term for intact orexin A that has not been metabolized and metabolites of orexin A that have been metabolized (truncated) only at a portion of the C-terminus. Orexin A and its metabolites that are recognized by a monoclonal antibody that recognizes the C-terminal side of orexin A and contain the amino acid sequence represented by SEQ ID NO: 1 are active orexin A.
[0056] In the present disclosure, quantification refers to determining the amount or concentration of a target substance present in a sample. Quantification can be absolute quantification or relative quantification. Relative quantification can be determining a relative amount compared to the amount of another analyte.
[0057] The sample may be cerebrospinal fluid, blood, plasma, serum or saliva, preferably cerebrospinal fluid.
[0058] The monoclonal antibody against orexin A is an antibody that recognizes the C-terminal side of orexin A. The C-terminal side of orexin A refers to the amino acid sequence from position 14 to position 33 in the amino acid sequence represented by sequence number 3 (the full length of orexin A). It can also be said that orexin A has an epitope relative to the above-mentioned monoclonal antibody in the amino acid sequence represented by sequence number 2. The above-mentioned monoclonal antibody may be an antibody produced by conventional hybridoma technology or a commercially available monoclonal antibody. The above-mentioned monoclonal antibody may be a mouse antibody, a rat antibody, a rabbit antibody, a goat antibody, a chimeric antibody or a humanized antibody.
[0059] The amino acid sequence represented by sequence number 1 is a sequence present near the N-terminus of orexin A, and is the amino acid sequence of positions 1 to 8 in the amino acid sequence represented by sequence number 3. The amino acid sequence represented by sequence number 2 is a sequence present near the C-terminus of orexin A, and is the amino acid sequence of positions 16 to 33 in the amino acid sequence represented by sequence number 3. The peptide consisting of the amino acid sequence represented by sequence number 1 can be obtained by digesting the separated orexin A class with a protease. As the protease, trypsin can be used.
[0060] In the method disclosed herein, orexin A can be separated by a known method. As such a known method, immunoprecipitation can be cited, but is not limited thereto. Immunoprecipitation can include, for example, a step of mixing magnetic beads bound to an antibody and a specimen containing cerebrospinal fluid; a step of centrifuging the obtained mixed solution and recovering the magnetic beads; and a step of eluting the target antigen from the recovered magnetic beads using a reducing agent.
[0061] The method disclosed in the present invention may further include a step of purifying the peptide consisting of the amino acid sequence represented by sequence number 1 by solid phase extraction before performing mass spectrometry analysis. As solid phase extraction methods, reverse phase solid phase extraction, normal phase solid phase extraction and ion exchange solid phase extraction can be listed. In the solid phase, fillers with silica as a carrier, fillers with polymers such as ion exchange resins as carriers, etc. are used. As columns used in solid phase extraction methods, columns having octadecyl fillers bound around silica gel carriers (C18 columns), columns having octyl fillers bound around silica gel carriers (C8 columns), columns having phenethyl fillers bound around silica gel carriers, columns having diol fillers bound around silica gel carriers, columns having aminopropyl fillers bound around silica gel carriers, etc. can be used.
[0062] In the method of the present disclosure, liquid chromatography may be performed before mass spectrometry. That is, the mass spectrometry of the present disclosure may be liquid chromatography-mass spectrometry. Examples of analysis conditions of liquid chromatography-mass spectrometry are shown in the Examples.
[0063] The method disclosed herein can be used to quantify the active orexin A in the sample collected from the subject, and diagnose or assist in diagnosing or assisting in diagnosing orexin A deficiency, sleep disorders, neurodegenerative diseases or traumatic brain injury based on the quantitative results. In addition, the method disclosed herein can be used to identify patients suffering from these diseases, etc. As sleep disorders, for example, difficulty falling asleep, awakening midway, shortened sleep time and difficulty waking up can be listed. As neurodegenerative diseases, for example, synuclein diseases, Tau protein diseases, etc. can be listed, and more specifically, Parkinson's disease, Alzheimer's disease, mild cognitive impairment, narcolepsy, Lewy body dementia, frontotemporal lobar degeneration, progressive supranuclear palsy, cortical basal ganglia degeneration, Huntington's disease, dystonia, prion disease, chorea-acanthocytosis, adrenoleukodystrophy, etc. Diagnosis or assist in diagnosing traumatic brain injury includes identifying the sleep disorder caused by traumatic brain injury.
[0064] In order to diagnose or assist in the diagnosis of orexin A deficiency, sleep disorders, neurodegenerative diseases or traumatic brain injury, for example, an approximate straight line showing the correlation between the amount of active orexin A and the amount of orexin A metabolites (C-terminal truncation) in the cerebrospinal fluid of patients who have been diagnosed with orexin A deficiency, sleep disorders, neurodegenerative diseases or traumatic brain injury can be prepared in advance, and the approximate straight line can be compared with the approximate straight line based on the quantitative results of undiagnosed patients (subjects). In some embodiments, the method described in this specification includes a step of determining whether the amount of active orexin A exceeds a predetermined cutoff value. The preset above-mentioned cutoff value can be the amount of active orexin A determined based on a receiver operating characteristic (ROC) analysis.
[0065] The subject may not have been diagnosed with orexin A deficiency, sleep disorders, neurodegenerative diseases or traumatic brain injury before diagnosis or auxiliary diagnosis by the method disclosed herein, or may have been diagnosed with these diseases, etc. In the latter case, the method disclosed herein can be performed to view the progression of the disease, the level of healing, etc.
[0066] Example
[0067] Below, the present disclosure is described in more detail based on the examples, but the present disclosure is not limited to the following examples. NC (Normal Control) refers to healthy people, PD refers to patients with Parkinson's disease, AD refers to patients with Alzheimer's disease, and MCI refers to patients with mild cognitive impairment. Hereinafter, when only "%" is described, it means "w / v%" (mass / volume %).
[0068] (Reference Example 1)
[0069] <Preparation of immunoprecipitation magnetic beads>
[0070] (1) A solution containing 0.2 mg of anti-orexin A mouse monoclonal antibody (recognizing the C-terminal side of orexin A, manufactured by Fujifilm Wako Pure Chemical Industries, Ltd., product number: 287-98321 (formerly manufactured by Wako Pure Chemical Industries, Ltd., original product number: 283-98323)) was placed in a plastic tube with an 8 kDa ultrafiltration dialysis membrane (GE Healthcare Cat#80648413) and solvent replaced in 2 L of 0.1 M NaHCO3, 0.5 M NaCl, pH 8.3 (hereinafter referred to as coupling buffer). (Stand overnight at 4°C for about 16 hours)
[0071] (2) 0.25 g of CNBr-activated Sepharose 4B magnetic beads (manufactured by Cytiva) were weighed and stirred in 1 L of a 1 mM hydrochloric acid aqueous solution for 20 minutes.
[0072] (3) The magnetic beads were recovered onto a glass Buchner funnel and washed with 25 mL of 1 mM hydrochloric acid aqueous solution.
[0073] (4) Wash twice with 25 mL of coupling buffer.
[0074] (5) The magnetic beads were collected into a 50 mL conical tube and centrifuged at 3500 rpm for 5 minutes.
[0075] (6) Remove all supernatant and add the antibody solution after solvent replacement.
[0076] (7) Visually add an equal volume of coupling buffer and magnetic beads.
[0077] (8) Rotate and stir at room temperature for 2 hours.
[0078] (9) Centrifuge at 3500 rpm for 5 minutes and remove the supernatant.
[0079] (10) Wash three times with 25 mL of coupling buffer. (Centrifugation at 3500 rpm for 5 minutes and removal of the supernatant were repeated)
[0080] (11) Centrifuge at 3500 rpm for 5 minutes. After removing the supernatant, add an aqueous solution of 1 M ethanolamine (pH 8 - 8.5, confirmed with pH test paper) until the volume is equal to that of the magnetic beads, and rotate and stir at room temperature for two hours.
[0081] (12) Recover the magnetic beads onto a glass Buchner funnel, and wash the recovered magnetic beads with 25 mL of pre-chilled 0.1 M sodium acetate + 0.5 M sodium chloride buffer (pH 4.0).
[0082] (13) Further wash the magnetic beads with 25 mL of pre-chilled 0.1 M trihydrochloride + 0.5 M sodium chloride buffer (pH 8.0).
[0083] (14) Repeat the washing with the buffer of pH 4.0 and the buffer of pH 8.0 a total of 4 times.
[0084] (15) Wash twice with 25 mL of phosphate-buffered saline (PBS).
[0085] (16) Prepare a 50 volume% slurry with 25 mL of PBS and store at 4 °C.
[0086] (Example 1)
[0087] <Quantification of specific orexin A in CSF (cerebrospinal fluid)>
[0088] (1) Add 400 μL of CSF from PD (or dissolve 500 pg of synthetic orexin A peptide in 400 μL of 1% BSA as a standard solution or use 400 μL of 1% BSA as a blank solution) into a polypropylene tube.
[0089] (2) Add 500 pg of stable isotope-labeled (leucine 13C-labeled) orexin A peptide (5 μL of a 100 ng / mL solution).
[0090] (3) Add 30 μL of the immunoprecipitation magnetic beads (50 volume% slurry) obtained in Reference Example 1.
[0091] (4) Rotate and stir at room temperature for 1.5 hours.
[0092] (5) Centrifuge at 3000 rpm for 1 minute, recover the supernatant into a new polypropylene tube, and then add 1 mL of 25 mM triethylammonium bicarbonate (TEABC) and wash the magnetic beads.
[0093] (6) Centrifuge at 3000 rpm for 1 minute. After removing the supernatant, add 1 mL of 25 mM TEABC and wash the magnetic beads. Repeat this step again, for a total of 3 washes.
[0094] (7) The mixture was centrifuged at 3000 rpm for 1 minute, the supernatant was removed, 20 μL of 5 mM dithiothreitol (in 25 mM TEABC) was added, and the mixture was incubated at 65°C for 30 minutes.
[0095] (8) Add 20 μL of 10 mM iodoacetamide (in 25 mM TEABC) and incubate at room temperature in the dark for 30 minutes.
[0096] (9) Add 40 μL of 10 μg / mL trypsin (in 25 mM TEABC) and incubate at 37°C overnight (about 16 hours).
[0097] (10) 100 μL of 25 mM TEABC was added and mixed, followed by centrifugation at 3000 rpm for 3 minutes to recover the supernatant.
[0098] (11) The supernatant was desalted using Toptip C18 (Glygen) under the following conditions (a) to (e).
[0099] (a) 50 μL of 60% acetonitrile aqueous solution + 0.1% formic acid was added to the column and centrifuged at 3000 rpm for 3 minutes.
[0100] (b) 200 μL of water + 0.1% formic acid was added to the column and centrifuged at 3000 rpm for 3 minutes.
[0101] (c) The supernatant obtained in step (10) was added to the column and centrifuged at 3000 rpm for 3 minutes.
[0102] (d) 200 μL of water + 0.1% formic acid was added to the column and centrifuged at 3000 rpm for 3 minutes.
[0103] (e) 100 μL of 60% acetonitrile aqueous solution + 0.1% formic acid was added to the column, and after centrifugation at 3000 rpm for 3 minutes, the sample was recovered in a 1.5 mL polypropylene tube.
[0104] (12) The recovered sample was stored at -80°C for 15 minutes to freeze the solution.
[0105] (13) Use a Speed-vac system for reduced pressure drying.
[0106] (14) After drying under reduced pressure, 27.5 μL of a 2% acetonitrile aqueous solution + 0.1% formic acid was added to the sample for redissolution.
[0107] (15) Centrifuge at 15,000 rpm for 3 min and transfer 25 μL of the supernatant to an LC / MS vial.
[0108] (16) Using the Orbitrap Fusion Lumos LC / MS system, the peptide consisting of the amino acid sequence represented by SEQ ID NO: 1 was accurately quantified under the following conditions, and the active orexin A was quantified. The results are shown in FIG. Figure 1 As shown. Figure 1 As shown, the result of t-test showed that the active orexin A in CSF of PD patients was significantly decreased compared with NC.
[0109] (Quantitative conditions)
[0110] Column: NANO HPLC capillary column (NTCC-360 / 100), manufactured by Nikkyo Technos, inner diameter 100 μm 150 mm
[0111] Column temperature: room temperature
[0112] Flow rate: 500nL / min
[0113] Injection volume: 5μL
[0114] Solvent:
[0115] Mobile phase A: 4% acetonitrile in water + 0.5% acetic acid
[0116] Mobile phase B: 80% acetonitrile in water + 0.5% acetic acid
[0117] 1% B (0 points) - 1% B (5 points) - 37% B (20 points) - 68% B (25 points) - 99% B (26 points) - 99% B (30 points)
[0118] Spraying voltage: 2000V
[0119] Purge gas: 1Arb
[0120] Ion transfer tube temperature: 275°C
[0121] Parallel reaction mode conditions
[0122] Quadrupole isolation window: 1m / z
[0123] Activation type: HCD
[0124] RF lens: 60%
[0125] AGC target: 500,000
[0126] The following peptides were detected in precise quantification:
[0127] C-terminal tryptic peptide (peptide consisting of the amino acid sequence represented by SEQ ID NO: 2) 621.3476 m / z, high energy collision dissociation (HCD) collision energy 30%, orbital trap resolution 60000
[0128] C-terminal tryptic peptide (stable isotope labelled) 633.0429 m / z, high energy collision dissociation (HCD) collision energy 30%, orbitrap resolution 30000
[0129] N-terminal tryptic peptide (peptide consisting of the amino acid sequence represented by SEQ ID NO. 1) 5514.7180 m / z, high energy collision dissociation (HCD) collision energy 20%, orbital trap resolution 60000
[0130] N-terminal tryptic peptide (stable isotope labelled) 518.2266 m / z, high energy collision dissociation (HCD) collision energy 20%, orbitrap resolution 30000
[0131] (Comparative Example 1)
[0132] In Example 1, the peptide consisting of the amino acid sequence represented by SEQ ID NO: 2 was quantified, but the peptide consisting of the amino acid sequence represented by SEQ ID NO: 1 was not quantified. Figure 2 As shown. Figure 2 As shown, when the amounts of orexin A metabolites with a C-terminus in the CSF were compared between PD patients and NCs and a t-test was performed, there was no significant difference.
[0133] (Comparative Example 2)
[0134] For the supernatant recovered in step (5) of Example 1, immunoprecipitation and mass spectrometry were performed in the same manner as in Example 1, except that immunoprecipitation magnetic beads bound to a polyclonal antibody (manufactured by Fujifilm Wako Pure Chemical Industries, Ltd., product number: 280-98311) were used instead of immunoprecipitation magnetic beads bound to a monoclonal antibody, and orexin A metabolites (orexin A truncated at the C-terminal end) were quantified. The results are as follows Figure 3 As shown. Figure 3 As shown, when the amount of C-terminally truncated orexin A metabolite in the CSF was compared between PD patients and NCs and a t-test was performed, there was no significant difference.
[0135] (Example 2)
[0136] The active orexin A in the cerebrospinal fluid of patients with Alzheimer's disease and mild cognitive impairment was quantified in the same manner as in Example 1. The results are shown together with the results of Example 1. Figure 4There was a trend toward decreased active orexin A in the CSF of patients with Alzheimer's disease and mild cognitive impairment compared with NC.
[0137] (Reference Example 2)
[0138] In the same manner as in Comparative Example 2, orexin A metabolites in the cerebrospinal fluid of patients showing Alzheimer's disease and mild cognitive impairment were quantified. Figure 5 The figure shows the correlation between the amount of active orexin A measured by the method of Example 1 (vertical axis) and the amount of orexin A metabolite (orexin A truncated at the C-terminal end) measured by the method of Comparative Example 2 (horizontal axis) in NC and cerebrospinal fluid of patients with PD, Alzheimer's disease, and mild cognitive impairment, respectively. Figure 5 As shown, a high correlation was observed in NC (determination coefficient = 0.82), but the correlation was low in the cerebrospinal fluid of patients with PD, Alzheimer's disease, and mild cognitive impairment (determination coefficient = 0.029-0.49). It is believed that the active orexin A in the cerebrospinal fluid of patients with PD, Alzheimer's disease, and mild cognitive impairment is particularly reduced.
[0139] (Example 3)
[0140] <Quantification of active orexin A in cerebrospinal fluid by LC / MS analysis>
[0141] <1> Add 400 μL of sample (cerebrospinal fluid collected over time from 5 healthy subjects) and calibration curve solution (a solution obtained by dissolving 0.8 pg, 1.6 pg, 4 pg, 10 pg, 50 pg, 100 pg or 400 pg of synthetic orexin A peptide in 400 μL of 1% BSA) or blank solution (1% BSA) to a polypropylene tube.
[0142] <2> Stable isotope (leucine 13C) labeled orexin A peptide (10 μL of a 200 ng / mL solution) was added.
[0143] <3> Immunoprecipitation was performed in the same manner as in (3) to (10) of Example 1, and the supernatant was recovered.
[0144] <4> Using OASIS (registered trademark) HLB elution plates (manufactured by Waters Corporation), the following conditions were used. ~ <e>The supernatant was desalted.
[0145] < / e> 300 μL of 60% acetonitrile aqueous solution + 0.1% formic acid was added and washed with suction.
[0146] 500 μL of water + 0.1% formic acid was added to the column and washed with suction.
[0147] <c>The above steps <3> The supernatant obtained was added to the column and suction was applied to allow adsorption.
[0148] <d>500 μL of water + 0.1% formic acid was added to the column and washed with suction.
[0149] <e>100 μL of 60% acetonitrile aqueous solution + 0.1% formic acid was added to the column, and the column was eluted by suction to recover the sample in a 1.5 mL polypropylene tube.
[0150] <5> The collected sample was dried and redissolved in the same manner as in (12) to (14) of Example 1. Active orexin A was quantified by LC / MS in the same manner as in (15) and (16) of Example 1, except that the quantification conditions were changed to the following conditions.
[0151] (Quantitative conditions)
[0152] Column: NANO HPLC capillary column (NTCC-360 / 75), manufactured by Nikkyo Technos, inner diameter 75 μm, 150 mm
[0153] Column temperature: room temperature
[0154] Flow rate: 400nL / min
[0155] Injection volume: 5μL
[0156] Solvent:
[0157] Mobile phase A: 4% acetonitrile in water + 0.5% acetic acid
[0158] Mobile phase B: 80% acetonitrile in water + 0.5% acetic acid
[0159] 5% B (0 points) - 5% B (5 points) - 32% B (20 points) - 68% B (25 points) - 99% B (26 points) - 99% B (30 points)
[0160] Spraying voltage: 2000V
[0161] Purge gas: 1Arb
[0162] Ion transfer tube temperature: 275°C
[0163] Parallel reaction mode conditions
[0164] Quadrupole isolation window: 1m / z
[0165] Activation type: HCD
[0166] RF lens: 60%
[0167] AGC target: 1000
[0168] (Comparative Example 4)
[0169] <Quantitative analysis of orexin A in human cerebrospinal fluid by EIA>
[0170] Use the Orexin A chemiluminescent EIA kit (manufactured by Phoenix) to quantitatively analyze orexin A in human cerebrospinal fluid according to the following steps. Human orexin A standard peptide (0pg / mL, 1pg / mL, 10pg / mL, 100pg / mL, 1000pg / mL or 10000pg / mL) serially diluted with 1x assay buffer and the sample to be quantitatively analyzed (undiluted, cerebrospinal fluid collected from five healthy people over time) are added to the wells. Then, add anti-orexin A polyclonal antibody dissolved in 1x assay buffer and mix, and incubate overnight at 4°C. Next, aspirate the reaction solution, add biotinylated orexin A, and incubate at room temperature for 1.5 hours. After washing 4 times with 1x assay buffer, add streptavidin-HRP diluted 1000 times with 1x assay buffer and incubate at room temperature for 1 hour. After washing four times with 1x assay buffer, the substrate solution was added to the wells and incubated at room temperature for 5 to 10 minutes. Then, the relative luminescence was read using an ELISA reader (manufactured by BMG LABTECH). A standard curve was prepared based on the signal of the human orexin A standard peptide to calculate the orexin A concentration in the cerebrospinal fluid.
[0171] < / e> < / d> < / c> Figure 6 This is a graph showing the amount of active orexin A in the cerebrospinal fluid of five test subjects measured using the method of Example 3 (vertical axis). Figure 6 Here, Auth-OXA refers to long orexin A (active orexin A) including the N-terminus, and IPMS refers to a method for quantifying active orexin A involved in the present disclosure. Figure 7 : is a graph showing the amount of orexin A (the total amount of the N-terminal orexin fragment containing active orexin A) (vertical axis) measured by the chemiluminescence-EIA method of Comparative Example 4. Figure 7 In this assay, OXA refers to orexin A and chemilumi-EIA refers to chemiluminescence-EIA. Figure 6 , 7 In the figure, the value on the vertical axis is a relative value (%) when the average of the measured values of each individual is set to 100%. Figure 6 , 7 Also shown is the fitting curve calculated with reference to Salomon, RM et al., Biol. Psychiatry 2003, 54, 96-104. Figure 6 , 7 The horizontal axis represents time. Figure 6 , 7 ID1 to ID5 refer to each of the five subjects.
[0172] like Figure 6 , 7 As shown, a circadian rhythm with a high amplitude was observed in the method involved in the present disclosure ( Figure 6 ), whereas a circadian rhythm with a significantly lower amplitude was observed in the chemiluminescence-EIA method of Comparative Example 4. ( Figure 7 )(p=0.0025). It is known that the amount of active orexin A varies greatly depending on the time of day and is considered to be related to the sleep-wake rhythm. In addition, it was found that the method of the present disclosure can more clearly determine the circadian rhythm of a subject.
Claims
1. A method for quantifying active orexin A in a sample, comprising: a step of contacting the sample with a monoclonal antibody that recognizes the C-terminal side of orexin A to separate orexin A; The step of digesting the separated orexin A class with a protease to obtain a peptide consisting of the amino acid sequence represented by SEQ ID NO: 1; as well as The step of performing mass spectrometry analysis on the peptide.
2. The method according to claim 1, further comprising the step of purifying the peptide by solid phase extraction before performing the mass spectrometry analysis.
3. The method according to claim 1 or 2, further comprising the step of performing high speed liquid chromatography before performing the mass spectrometry analysis.
4. The method according to any one of claims 1 to 3, wherein the orexin A class is isolated by immunoprecipitation.
5. A method for quantifying active orexin A in a sample collected from a subject using the method according to any one of claims 1 to 4, and assisting in the diagnosis of orexin A deficiency, sleep disorders, neurodegenerative diseases or traumatic brain injury based on the quantitative results. The method according to claim 5 , which is a method for assisting diagnosis of neurodegenerative diseases.
7. The method according to claim 5 or 6, wherein: The sample collected from the subject is cerebrospinal fluid.
8. The method according to any one of claims 5 to 7, wherein: The neurodegenerative disease is a synucleinopathy or a tauopathy.
9. The method according to any one of claims 5 to 8, wherein: The neurodegenerative disease is Parkinson's disease, Alzheimer's disease or mild cognitive impairment.
